Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02582697 · ClinicalTrials.gov registry record · Phase 3

Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

A Phase 3 study of Germ Cell Tumor, sponsored by University of Sydney.

Recruiting
Registry status
Phase 3
Development phase
500
Enrollment target
20
Study locations

NCT02582697 is a Phase 3 study of Germ Cell Tumor that is actively recruiting participants, run by University of Sydney. The registered enrollment target is 500 participants, above the 321-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (56% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02582697, a Phase 3 study of Germ Cell Tumor, is actively recruiting participants, sponsored by University of Sydney.

RECRUITING
Registry status
Phase 3
Development phase
500 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Conditions Studied

Germ Cell Tumor

Interventions

  • DRUG Cisplatin
  • DRUG Etoposide
  • DRUG Filgrastim
  • DRUG Bleomycin (active name: Bleomycin Sulfate)
  • DRUG Pegylated G-CSF (Pegfilgrastim)

Study Locations (20)

New South Wales

  • Calvary Mater Newcastle - Newcastle
  • Royal North Shore Hospital - St Leonards
  • Prince of Wales Hospital - Sydney
  • Chris O'Brien Lifehouse - Sydney
  • Macquarie Cancer Clinical Trials - Sydney
  • Concord Repatriation General Hospital - Sydney
  • Westmead Hospital - Sydney
  • Nepean Hospital - Sydney
  • Tweed Hospital - Tweed Heads
  • SAN Clinical Trials Unit - Wahroonga

Queensland

  • Royal Brisbane & Women's Hospital - Brisbane
  • Queensland Children's Hospital - South Brisbane
  • Princess Alexandra - Woolloongabba

Victoria

  • Box Hill Hospital - Box Hill
  • Peter MacCallum Cancer Centre - East Melbourne
  • Austin Health - Heidelberg

South Australia

  • Royal Adelaide Hospital - Adelaide
  • Flinders Medical Centre - Bedford Park

New York

  • Memorial Sloan Kettering Cancer Centre - New York

Tasmania

  • Royal Hobart Hospital - Hobart

Trial Details

FieldValue
Enrollment Target 500 participants
Start Date 2014-02
Est. Completion 2029-12-31
Phase Phase 3

Sponsor

University of Sydney

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02582697

The ClinicalTrials.gov registry entry for NCT02582697 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 321-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (56% higher). The listed sponsor is University of Sydney, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Germ Cell Tumor appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.

NCT02582697 reports 20 study locations spanning 6 distinct geographic areas - top geographies include New South Wales, Queensland, Victoria.

Frequently Asked Questions

What is clinical trial NCT02582697 about?

NCT02582697 is a clinical study titled "Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours". The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

What is the current status of trial NCT02582697?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2014-02. Estimated completion is 2029-12-31.

What conditions does trial NCT02582697 study?

This clinical trial studies the following conditions: Germ Cell Tumor.

What interventions are being tested in trial NCT02582697?

The interventions under investigation include: Cisplatin (DRUG), Etoposide (DRUG), Filgrastim (DRUG), Bleomycin (active name: Bleomycin Sulfate) (DRUG), Pegylated G-CSF (Pegfilgrastim) (DRUG).

Who is sponsoring clinical trial NCT02582697?

This trial is sponsored by University of Sydney, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02582697 being conducted?

This trial has 20 study locations across New York, New South Wales, Queensland, South Australia, Tasmania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Germ Cell Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Germ Cell Tumor

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.